X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biopharmadive.com/news/neurocrine-depression-study-medicine-takeda-results/714001/
https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1065845-in-adults-with-major-depressive-disorder-302123889.html
https://www.globenewswire.com/news-release/2024/04/16/2863300/0/en/Nxera-Pharma-Notes-Successful-Development-Progress-of-Partnered-Schizophrenia-Candidate-NBI-1117568.html
https://www.globenewswire.com/news-release/2024/04/16/2864079/0/en/Sentia-Medical-Sciences-and-Neurocrine-Biosciences-Extend-Research-Collaboration-to-Discover-Novel-CRF-Peptides.html
https://www.globenewswire.com/news-release/2024/04/16/2863436/36461/en/Voyager-Therapeutics-Announces-Selection-of-Development-Candidate-for-GBA1-Program-in-Collaboration-with-Neurocrine-Biosciences-Triggering-Milestone-Payment.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2024-financial-results-302113406.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-nbi-1070770-in-adults-with-major-depressive-disorder-302106187.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-effects-of-nbi-1065890-a-second-generation-vmat2-inhibitor-in-healthy-adults-302101715.html
https://finance.yahoo.com/news/director-richard-pops-sells-shares-052605436.html#:~:text=Richard%20Pops%2C%20Director%20of%20Neurocrine,a%20total%20value%20of%20%24252%2C072.
Market Place
Share 
